ABSTRACT

Background: Polyomavirus BK is a major cause of nephropathy in immunosuppressed transplanted patients. Non-invasive diagnostic protocols such as molecular detection of polyomavirus BK replication are a useful strategy to predict BK virus-associated nephropathy (BKVAN).

Objective: To determine the prevalence of polyomavirus BK infection among kidney transplant patients suspected to have BKVAN.

Methods: In a cross-sectional study 108 kidney transplanted patients whose laboratory and clinical presentation were in favor of nephropathy between 2010 and 2012, were enrolled for analysis. Polyomavirus BK replication was evaluated in plasma and tissue samples of studied patients using a quantitative real-time PCR. Active cytomegalovirus infection was analyzed in studied patients using antigenemia method. A possible association between polyomavirus BK infection with clinical and laboratory risk factors of BKVAN were evaluated.

Results: The polyomavirus BK replication was found in 17 (15.7%) of 108 of plasma and 9 (11%) of 82 tissue samples in kidney transplanted patients. Cytomegalovirus co-infection was found in 3 of 17 and 3 of 9 plasma and tissue samples in polyomavirus BK infected patients, respectively. Significant associations were found between polyomavirus BK infection with tubulointerstitial nephritis and acute cellular rejection, as important pathologic findings of BKVAN.

Conclusion: Diagnosis of single and co-infection of polyomavirus BK infection in plasma samples is a useful assay to evaluate the risk of BKVAN in kidney transplant patients. Established threshold values for studied viral infections have beneficial use in screening of kidney transplant patients at risk of BKVAN, need to confirm and standardized in completed further studies.

KEYWORDS: Polyomavirus BK; Nephropathy; Kidney transplantation
immunosuppressed transplant patients, latent polyomavirus BK can reactivate [3, 4, 11, 10], leading to unrestricted high viral DNA load in infected tissues and cytolylotic destruction of viral target cells [7]. Similar DNA sequences with polyomavirus BK genomic DNA have been observed in renal tissue of healthy normal individuals using hybridization protocols [8]. Polyomavirus BK is as a major cause of kidney allograft dysfunction, cystitis, ureteral stenosis, nephropathy—BK virus-associated nephropathy (BKVAN)—and potential graft loss [4, 11]. Risk factors associated with BKVAN are not known, but introduction of the systematic use of potent immunosuppressive regimens has played an important role [4, 11]. Recipient conditions such as infection or rejection episodes, donor characteristics, such as anti-polyomavirus BK seropositivity and gender, graft features, such as long cold ischemic time can promote polyomavirus BK replication [11]. Its frequency among kidney transplant recipients is usually high (10%–60%) [1, 8, 9, 12]. BKVAN was detected in 1%–10% in renal allograft recipients with loss of renal allograft ranging from 10%–80% [5, 9, 11, 13-15]. Serum creatinine level and urine protein/creatinine ratio (total protein excretion) should be used to screen and follow changes in renal function [16]. So far, no specific antiviral drug is available and the management of BKVAN is merely based on reduction of the immunosuppressive drugs [17]. Immunosuppressive treatment with tacrolimus, mycophenolate, and recently, basiliximab, showed significant associations with the development of detectable polyomavirus BK viremia [11, 17-19]. Before introduction of noninvasive diagnostic tests for polyomavirus BK replication, BKVAN was mostly diagnosed in an advanced stage when irreversible tissue damage had been occurred leading to allograft loss in as many as 90% of transplanted patients [6]. In these patients, histological examination of the allograft biopsy specimens revealed extensive replication of the virus, cell necrosis in the tubules and collecting ducts, and varying degrees of interstitial inflammation [6]. Therefore, early detection of polyomavirus BK replication is feasible and important basic strategy in early diagnosis and treatment of BKVAN to prevent the associated nephropathy [6, 20].

Simultaneous co-infection with other viruses can induce BKVAN. Cytomegalovirus-like polyomavirus BK is capable of establishing lifelong latent infection. Reactivation of these viral infections is important cause of post-transplant outcomes. However, the underlying mechanism is not completely clear [21-23].

New molecular methods including PCR and real-time PCR have significantly contributed to the rapid, sensitive, and non-invasive diagnosis of polyomavirus BK [24]. Severity, clinical course, and therapeutic response of BKVAN have all been linked to polyomavirus BK load in urine and blood [25]. Furthermore, viral load determination in blood has significantly been associated with BKVAN [9]. Several studies have demonstrated a correlation between higher viral load in plasma and disease, with positive predictive value ranging from 60% to 85% [4, 11, 12, 25]. Therefore, in this study the frequency of polyomavirus BK infection was evaluated in tissue and blood samples to analyze the possible association between polyomavirus BK infection with post-transplant nephropathy.

**MATERIALS AND METHODS**

Patients and Samples

In a cross-sectional study, 108 kidney transplant patients with rising creatinine level >1.5 mg/dL, glomeruli filtration rate (GFR) <30 mL/min/1.73 m² body surface area, and nephropathy symptoms admitted to Namazi Hospital, affiliated to Shiraz University of Medical Sciences, Shiraz, Iran, between 2010 and 2012, were enrolled in this study. The study was approved by the Ethics Committee of Shiraz University of Medical Sciences (the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki). One EDTA-treated blood and one tissue samples were collected from each kidney transplant patient. One tissue sample was also collected from 82 of 108 studied kidney transplant patients. Donors were selected based on ABO blood group compatibility; all of them were...
negative for cross-matches. The standard conditioning regimen for studied patients included cyclosporine 5 mg/kg initially, a maintenance dose of 2–2.5 mg/kg; cyclosporine level was 50-150 ng/mL; prednisolone 120 mg/day initially, tapering to 10 mg/day; and mycophenolate mofetil 1000 mg/day, twice daily. Acute rejection was initially treated with intravenous steroids. Patients with steroid-resistant rejection were treated with OKT3 [17]. Intravenous acyclovir, 750 mg/day, was administered from day three before transplantation for herpesvirus prophylaxis. A possible association of polyomavirus BK infection with risk factors including pathology results, age, sex, Cellsept, prednisolone, cyclosporine, FK, and creatinine levels and cytomegalovirus infection were evaluated in tissue and plasma samples of studied kidney transplant patients.

Viral Genome Extraction
Polyomavirus BK was extracted from plasma and tissue samples using the Invisorb® Spin Virus DNA Blood Mini kit (Invitek, Germany) according to the manufacturer’s instruction.

Polyomavirus BK Quantitative PCR
Quantification of polyomavirus BK genome load was done using Genesig BKV real-time PCR (Primer Design Ltd TM, Advanced kit, UK). The standard was prepared using 10-fold dilution of positive control included in the BKV real-time PCR. Polyomavirus BK PCR mix in a final reaction volume of 20 μL containing 5 μL of the DNA, 10 μL Precision™ MasterMix (Applied Biosystems), 1 μL primers and a probe targeting the polyomavirus BK NCCR sequence, 1 μL primers and a probe targeting the internal control (IC) gene, and 3 μL DEPS water. The thermocycling condition for polyomavirus BK included one cycle at 95 °C for 10 min followed by 50 cycles at 95 °C for 5 sec and 60 °C for 60 sec using Step One Plus real-time thermocycler (Applied Biosystems, USA). This quantitative PCR assay was sensitive enough to detect 10 copies of polyomavirus BK genomic DNA per mL of body samples.

Cytomegalovirus Antigenemia Protocol
Cytomegalovirus antigenemia was performed on EDTA-treated blood samples to evaluate the presence of lower matrix pp65 antigen in polymorph nuclear cells using the CMV Brite Turbo kit (IQ Products, Groningen, Netherlands) according to manufacturer’s instruction as previously described [26].

Statistical Analysis
Data were analyzed by SPSS ver 15. χ², Fisher exact test, and Mann-Whitney U test were used to analyze demographic and laboratory indices that may relate to results of polyomavirus BK PCR. A p value <0.05 was considered statistically significant.

RESULTS
The mean age of 108 (65 male and 43 female) studied kidney transplant patients was 40 (range: 15–68) years.

Polyomavirus BK Infection
Polyomavirus BK infection was found in 17 (15.7%) of 108 of plasma and 9 (11%) of 82 tissue samples post-kidney transplantation. The polyomavirus BK load in positive plasma samples was >100 copy/mL and <100 copy/mL in tissue samples. The prevalence of polyomavirus BK load in plasma and tissue samples was more elevated in the first year compared with the second and third year post-transplantation follow-up visits. The plasma samples of 6 (5.6%) men and 11 (10.2%) of women of 108 patients were positive for polyomavirus BK infection. The tissue samples of 3 (4%) males and 6 (7%) females of 82 patients studied were found positive for polyomavirus BK infection (Table 1).

Cytomegalovirus Co-infection
Active cytomegalovirus infection was found in 13 (12%) of 108 transplant patients. Co-infection with cytomegalovirus was found in 2 of 17 plasma and 3 of 9 tissue samples infected with polyomavirus BK (Table 1).

Polyomavirus BK infection and Risk Factors
Associations between various risk factors and infection with polyomavirus BK detected in
| No | Age (yrs) | Sex   | Creatinine (mg/dL) | Cellcept (mg) | Cyclosporine (mg/kg/day) | Tacrolimus (mg/kg/day) | Prednisolone (mg/mL) | Pathology decision                                                                 | Polyomavirus BK infection in plasma | Polyomavirus BK infection in tissue | Transplant duration (months) | Polyomavirus BK copy number (genome copy/mL) | Cytomegalo-virus active infection (PP65 antigenemia) |
|----|-----------|-------|--------------------|---------------|---------------------------|------------------------|---------------------|-----------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------------------------------|-----------------------------------------------|
| 1  | 22        | Male  | 7                  | 500           | NFD                       | 2                      | 10                  | Acute cellular rejection grade (IIb), acute tubular necrosis      | +                                 | -                                | 9                                 | 26600                         | NFD                             |
| 2  | 31        | Male  | 1.7                | 1500          | NFD                       | 3                      | 5                   | C4d+, no rejection                                                 | -                                 | +                                | 11                               | 20                            | NFD                             |
| 3  | 44        | Female | 1.8               | 2000          | NFD                       | 3                      | 5                   | Acute tubulointerstitial nephritis                              | +                                 | -                                | 4                                 | 20                            | NFD                             |
| 4  | 20        | Female | 2.4               | 2000          | NFD                       | 2                      | 2.5                 | Chronic allograft nephropathy (grade I)                          | -                                 | +                                | 12                               | 20                            | +                               |
| 5  | 15        | Male  | 5.2                | 1000          | 100                       | NFD                    | 5                   | Acute tubulointerstitial nephritis, chronic allograft nephropathy (grade I) | -                                 | +                                | 26                               | 20                            | NFD                             |
| 6  | 33        | Male  | 2.8                | 1500          | NFT                       | 3                      | 25                  | Acute cellular rejection grade (Ib)                             | +                                 | -                                | 11                               | 20                            | NFD                             |
| 7  | 44        | Male  | 1.6                | 2000          | 200                       | NFD                    | 7.5                 | Acute cellular rejection grade (Ia), chronic allograft nephropathy (grade I) | +                                 | -                                | 34                               | 20                            | NFD                             |
| 8  | 33        | Male  | 8.4                | 1000          | NFT                       | 2                      | 20                  | Acute cellular rejection grade (Iib)                            | +                                 | -                                | 28                               | 20                            | +                               |
| 9  | 63        | Female | 2.5               | 2000          | 100                       | NFD                    | 5                   | Acute tubulointerstitial nephritis, chronic allograft nephropathy (grade I) | -                                 | +                                | 15                               | 40                            | NFD                             |
| 10 | 38        | Female | 2.5               | 1500          | NFD                       | 3                      | 5                   | NFD                                                             | +                                 | -                                | 18                               | 20                            | +                               |
| 11 | 20        | Female | 3.5               | 1500          | 250                       | NFD                    | 15                  | Acute cellular rejection                                        | -                                 | +                                | 15                               | 20                            | +                               |
| 12 | 43        | Female | 6                 | 2000          | NFD                       | 3                      | 5                   | Acute tubulointerstitial nephritis                              | -                                 | +                                | 11                               | 20                            | +                               |
| 13 | 42        | Female | 4                 | 1000          | NFD                       | 2                      | 5                   | Acute cellular rejection (grade Ia)                             | +                                 | -                                | 5                                | 120                           | NFD                             |
| 14 | 50        | Female | 2.8               | 1000          | NFD                       | 1                      | 7.5                 | Acute cellular rejection                                        | -                                 | +                                | 3                                | 20                            | NFD                             |
| 15 | 27        | Male  | 8                  | 1000          | NFD                       | NFD                    | 5                   | Acute tubulointerstitial nephritis, acute cellular rejection (grade I), chronic allograft nephropathy (grade I) | +                                 | -                                | 3                                | 20                            | NFD                             |
| 16 | 45        | Male  | 2.4                | 2000          | NFD                       | 4                      | 5                   | Acute cellular rejection                                        | Neg                               | +                                | 13                               | 20                            | NFD                             |
| 17 | 30        | Female | 2.5               | 2000          | NFD                       | 3                      | 5                   | Acute cellular rejection (grade Ia), Ab-mediated, C4d+ and no rejection | +                                 | -                                | 13                               | 50                            | NFD                             |
| 18 | 36        | Female | 6.3               | 2000          | NFD                       | 4                      | 5                   | Acute cellular rejection, acute tubular necrosis                 | Neg                               | +                                | 9                                | 20                            | NFD                             |
plasma and tissue samples of kidney transplanted patients are shown in Table 2. Significant associations were found between polyomavirus BK infection in tissue samples with tubulointerstitial nephritis (p=0.001) and acute cellular rejection (p=0.022) (Table 2). There were no significant correlations between polyomavirus BK infection with other pathology results.

**DISCUSSION**

Polyomavirus BK nephropathy remains important as a post-kidney transplant complication. No clinical risk factors absolutely relates to development of this viral-related nephropathy. Treatment of BKVAN is also problematic and no antiviral medication is approved. Monitoring anti-polyomavirus BK specific immunity is also not widely available. Therefore, molecular screening of polyomavirus BK replication and targeted reduction of immunosuppression can resolve infection and improve renal function by stabilizing serum creatinine in kidney transplanted patients [12, 27]. From patient samples, serial screening of plasma polyomavirus BK load is a valid tool to identify patients at risk of BKVAN [4]. Such finding becomes even more relevant because BK viremia only occurs under active replication not being found during latent infections [11, 12, 17]. However, researchers recently reported marked variability between commonly used polyomavirus BK load assays [28, 29]. Furthermore, neither polyomavirus BK real-time PCR nor the cut-off value for significant viral replication has been standardized [6]. Therefore, a threshold value should be established for each different quantitative polyomavirus to clearly screen BKVAN.

In this study the polyomavirus BK infection was studied in kidney transplanted patients with elevated level of creatinine and risk of BKVAN. Polyomavirus BK load was found in 15.7% of plasma and 11% of tissue samples. The polyomavirus BK load was >100 copy/mL in plasma and <100 copy/mL in tissue samples. Also polyomavirus BK load in plasma and tissue samples was more elevated in the

| No. | Age (yrs) | Sex | Creatinine (mg/dL) | Cell Cipt (mg) | Cyclosporine (mg/kg/day) | Tacrolimus (mg/kg/day) | Prednisolone (mg/mL) | Pathology decision | Polyomavirus BK infection in plasma | Polyomavirus BK infection in tissue |
|-----|----------|-----|-------------------|---------------|------------------------|------------------------|-------------------|------------------|-------------------------------|----------------------------------|
| 19  | 54       | Female | 3.5 | 1000           | 2                       | 10                     | Acute tubulointerstitial nephritis, acute cellular rejection | +                | +                             | +                                |
| 20  | 75       | Male   | 3.2 | 1500           | 5                      | 5                      | NFD                | NFT              | NFT                           | NFT                              |
| 21  | 65       | Male   | 2.8 | 2000           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |
| 22  | 51       | Male   | 2.8 | 2000           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |
| 23  | 34       | Male   | 2.8 | 2000           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |
| 24  | 36       | Female | 1.7 | 1500           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |
| 25  | 30       | Male   | 1.7 | 1500           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |
| 26  | 31       | Male   | 1.8 | 1500           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |
| 27  | 31       | Male   | 1.8 | 1500           | 2                      | 2                      | NFT                | NFT              | NFT                           | NFT                              |

a: +=Positive; –=Negative; b: NFD=Data not found, c: +=Rate antigenemia positivity
first year compared with the second and third year post-transplantation follow-up visits. In a study, the rate of BKVAN was found in 36 (2%) of 1788 kidney transplant patients [9, 29, 30]. In other single-center reports the rate of polyomavirus BK load was 7.5% [6, 30]. Similarly in another report the polyomavirus BK load was found in 7 (35%) of 26 transplanted recipients [4]. A retrospective analysis of urine and plasma samples of 30 kidney recipients found that eight (27%) patients were positive for polyomavirus BK viruria [13]. The overall prevalence of polyomavirus BK DNAuria and DNAemia were 40.7% and 9.2% in 76 studied transplant patients, respectively [14]. In another retrospective cohort, the rate of BKVAN was 3.7% [11]. The plasma PCR was superior to urine PCR or cytology in specificity and positive predictive value for detection of BKVAN. Regular monitoring of plasma PCR detected significant polyomavirus BK viremia in 8.9% of patients [19]. Plasma PCR is useful in predicting an increased risk for BKVAN [6]. In another investigation, polyomavirus BK viremia was found in 43.3% of kidney recipients [28]. However, in controversy with this report and other earlier studies, Hammarin, et al, was not found any patients with BKVAN and any transplanted patients with a permanent deterioration of graft function. After six years of monitoring these kidney transplanted patients, it was clearly shown that patients with low viral loads were often intermittently became positive for polyomavirus BK DNAemia for long periods and this viremia has no clinical relevance in the majority of patients [17].

In their study, 8.3% of patients were positive for Epstein-Barr virus. Moreover, Nada, et al, reported coexistence of cytomegalovirus and BKV infections in a biopsy specimen from a patient who experienced acute rejection [8]. From these reports, it may be suggested that cytomegalovirus infection is associated with BKV infection, and vice versa, which differs from results of the present study. However, all of these studies reported co-infection with these two viruses, whereas the present study examined only the coexistence of these viruses. Therefore, positivity for one virus does not necessarily mean acute infection.

Several risk factors have been associated with increased polyomavirus BK replication and nephropathy progression, including warm ischemia and reperfusion injury, cytomegalovirus co-infection, the level of panel reactive antibodies, duration of dialysis, and the type of immunosuppressive therapy [31, 32]. Cytomegalovirus and polyomavirus BK co-infection may have role on promoting or limiting their related pathogenesis [21-23]. Polyomavirus BK virus may induce the expression of cytomegalovirus genes by stimulating cellular regulator proteins and/or by its related gene regulator proteins [21-23]. Coexistence of these viral infections has been reported with controversy in kidney transplant recipients with allograft nephropathy [22, 23]. In this study, also 11.8% and 33.3% of plasma and tissue

| Risk Factors                          | Plasma | Tissue |
|--------------------------------------|--------|--------|
| Sex                                  | 0.552  | 0.135  |
| Age                                  | 0.418  | 0.148  |
| Cellcept                             | 0.225  | 0.373  |
| Prednisolone                         | 0.622  | 0.335  |
| Cyclosporine                         | 0.897  | 0.600  |
| Tacrolimus                           | 0.673  | 0.455  |
| Creatinine                           | 0.849  | 0.905  |
| Tubulointerstitial nephritis         | 0.430  | 0.001  |
| Acute cellular rejection             | 0.377  | 0.022  |
sue samples of kidney transplanted recipients were simultaneously co-infected with polyomavirus BK.

However, it remains unclear whether specific immunosuppressive agents or their respective doses are critical to BKVN development [32]. In some studies higher viruria was found in treatment regimens combined of tacrolimus and mycophenolate mofetil compared with cyclosporine and mycophenolate mofetil [9, 11, 32]. However, in this study significant association was found only between viral load in tissue samples with two pathology results tubulointerstitial nephritis and with acute cellular rejection. Similar to some reports [29], significant associations were not seen between polyomavirus BK infection and other risk factors including age, sex, use of Cellcept, prednisolone, and cyclosporine, FK, and creatinine levels. Similar to another report [6], in this study cytomegalovirus co-infection was found in only one patient with polyomavirus BK infection.

In conclusion, based on these results, measurement of polyomavirus BK replication in plasma in comparison with tissue samples is a valuable assay to evaluate the risk of BKVAN in kidney transplant patients. Established threshold value, which has beneficial use in screening of Iranian kidney transplant patients at risk of polyomavirus BK-related nephropathy in Iranian kidney transplant patients, need to confirm and standardized in completed further studies.

ACKNOWLEDGMENTS

The study was financially supported using a grant from Shiraz University of Medical Sciences.

REFERENCES

1. Kroth LV, Henkin CS, Peres LD, et al. Prevalence of urinary decoy cells and associated risk factors in a Brazilian kidney, pancreas, and kidney-pancreas transplant population. Transplant Proc 2012;44:2394-6.

2. Razonable RR, Brown RA, Humar A, et al. Study Group. A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis 2005;192:1349-54.

3. Arthur RR, Dagostin S, Shah KV. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol 1989;27:1174-9.

4. Pollara CP, Corbellini S, Chiappini S, et al. Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. New Microbiol 2011;34:165-71.

5. Marinelli K, Bagnarelli P, Gaffi G, et al. PCR real time assays for the early detection of BKV-DNA in immunocompromised patients. New Microbiol 2007;30:275-8.

6. Chung BH, Hong YA, Kim HG, et al. Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virus associated nephropathy. Transpl Int 2012;25:687-95.

7. Casini B, Borgese L, Del Nonno F, et al. Presence and incidence of DNA sequences of human polyomaviruses BKV and JCV in colorectal tumor tissues. Anticancer Res 2005;25:1079-85.

8. Goudsmit J, Wertheim-van Dillen P, van Strien A, et al. The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol 1982;10:91-99.

9. Lipshutz GS, Mahanty H, Feng S, et al. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant 2005;5:366-73.

10. Mitterhofer AP, Pietropaolo V, Barile M, et al. Meaning of early polyomavirus-BK replication post kidney transplant. Transplant Proc 2010;42:1142-5.

11. Barraclough KA, Isbel NM, Staatz CE, et al. BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. J Transplant 2011.

12. De Moura Montagner J, Michelon TF, Schroeder RB, et al. Polyomavirus–an emergent pathogen in transplant recipients. Einstein 2007;5:184-9.

13. Taheri S, Kafilzadeh F, Shafa M, et al. Comparison of polyomavirus (BK virus and JC viruses) viruria in renal transplant recipients with and without kidney dysfunction. J Res Med Sci 2011;16:916-22.

14. Burgos D, Jironda C, Martin M, et al. [BK-virus-associated Nephropathy]. Nefrologia 2010;30:613-7.

15. Almeras C, Vetromile F, Garrigue V, et al. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis 2011;13:101-8.

16. Mischitelli M, Bellizzi A, Anzivino E, et al. Complications post renal transplantation: literature focus on BK virus nephropathy and diagnostic tools actually available. Virol J 2008;5:38.

17. Hammarin AL, Oqvist B, Wahlgren J, et al. System-
atic screening of BK virus by real-time PCR prevents BK virus associated nephropathy in renal transplant recipients. J Med Virol 2011;83:1959-65.

18. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008;3:68-75.

19. Ferreira-Gonzalez A, Sidiqui R. BK virus in the transplant patient. Clinical Microbiology Newsletter 2007;29:121-8.

20. Costa C, Bergallo M, Astegiano S, et al. Monitoring of BK virus replication in the first year following renal transplantation. Nephrol Dial Transplant 2008;23:3333-6.

21. Park SB, Kwak JH, Lee KT, et al. Polyoma Virus-Associated Nephropathy and Concurrent Cytomegalovirus Infection in the Kidney Transplant Recipients. Transpl Proc 2006;38:2060-1.

22. Toyoda M, Puliyanda DP, Amet N, et al. Co-infection of polyoma virus–BK and cytomegalovirus in renal transplant recipients. Transplantation 2005;80:198-205.

23. Nada R, Sachdeva MUS, Sud K, et al. Co-infection by cytomegalovirus and BK polyoma virus in renal allograft, mimicking acute rejection. Nephrol Dial Transplant 2005;20:994-6.

24. Echavarria M, Basilotta N, Aguiar A, et al. BK virus nephropathy after renal transplantation. Diagnosis and prognosis by real time PCR. Medicina (B Aires) 2007;67:719-22.

25. Gu Z, Pan J, Bankowski MJ, et al. Quantitative Real-Time Polymerase Chain Reaction Detection of BK Virus Using Labeled Primers. Arch Pathol Lab Med 2010;134:444-8.

26. Saadi MI, Yaghobi R, Karimi MH, et al. Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients. Mol Biol Rep 2013;40:833-5842.

27. Boudreault AA, Courtemanche C, Latulippe E, et al. Screening for polyomavirus associated nephropathy in renal transplantation with blood viral load measurement. J Clin Virol 2009;45:318-21.

28. Miller S, Liverman CS, Post L, et al. Analytical and clinical performance characteristics of the Simplexa BK virus quantitative PCR assay for the diagnosis of polyomavirus-associated nephropathy in renal transplant recipients using plasma and urine specimens. J Clin Virol 2012;55:310-16.

29. Al-Jedai AH, Honaker MR, Trofe J, et al. Renal allograft loss as the result of polyomavirus interstitial nephritis after simultaneous kidney-pancreas transplantation: results with kidney retransplantation. Transplantation 2003;75:490-4.

30. Trofe J, Gaber LW, Stratta RJ, et al. Polyomavirus in kidney and kidney–pancreas transplant recipients. Transpl Infect Dis 2003;5:21-8.

31. Girmanova E, Brabcova I, Bandur S, et al. A prospective longitudinal study of BK virus infection in 120 Czech renal transplant recipients. J Med Virol 2011;83:1395-1400.

32. Vats A, Randhawa P, Shapiro R, et al. BK Virus: Discovery, Epidemiology, and Biology. Graft 2002;5:19-27.